Nov 14 |
Organon: 7% Yield, 4x P/E, Big Upside Potential
|
Nov 13 |
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
|
Nov 8 |
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
|
Nov 5 |
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
|
Nov 5 |
Organon updates outlook as FDA delays VTAMA label expansion
|
Nov 5 |
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
|
Nov 3 |
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
|
Nov 1 |
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)
|
Oct 31 |
Organon & Co. 2024 Q3 - Results - Earnings Call Presentation
|
Oct 31 |
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
|